ReviewCurrent medicinal chemistry2025
Ginsenoside Rg3 in Cancer Research: Current Trends and Future Prospects - A Review.
Review in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Ginsenoside Rg3 promotes chemosensitivity in lung adenocarcinoma organoids via apoptotic pathways.Frontiers in pharmacology · 2026Article
- Targeting Lysosomes for Enhanced Anti-Cancer Therapeutics and Immune Response.International journal of biological sciences · 2026Review
- Natural Combatants: How Herbal Monomers Regulate Autophagy in Ovarian Cancer.Anti-cancer agents in medicinal chemistry · 2026Review
- Genomic and metabolomic insights into the enhancement of rare ginsenosides inFrontiers in microbiology · 2026Article
- Microbial Fermentation Affects the Structure-Activity Relationship of Bioactive Compounds in Ginseng and Its Applications in Fermentation Products: A Review.Foods (Basel, Switzerland) · 2025Review
- Efficacy and Safety of Shenyi Capsule (Ginsenoside Rg3) as Adjuvant Therapy for Cancer: An Overview of Systematic Reviews and Meta-Analyses.Integrative cancer therapiesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is one of the most devastating illnesses in the world, impacting millions of individuals every year. Despite various therapies, the final effect is unsatisfactory. Chemotherapy currently dominates as the primary option of treatment. However, its severe adverse effects, limited efficacy, and resistance to drugs undermine its potential. Growing evidence suggests that ginsenoside Rg3, a natural compound obtained from the ginseng plant (Panax ginseng), holds significant promise in cancer therapy. Its proposed mechanisms primarily involve the enhancement of immunity, retardation of cancer cellular proliferation and metastasis, triggering apoptosis, angiogenesis, epigenetic modification, and Regulation of transition of epithelial mesenchyma (EMT) and miRNAs/lncRNA. Furthermore, Rg3-ginsenoside potentiates the effectiveness of conventional treatments of cancer and reduces the adverse effects through synergistic interactions. Ginsenoside Rg3's present status in cancer research is thoroughly reviewed in this article, shedding light on its intricate mechanisms and potential to revolutionize cancer therapy through combinatorial and nano-based targeted therapy.
Indexed as
Identifiers
39817388What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.